Publication | Closed Access

Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial

UrologyGenitourinary CancerMedicineRandomised Phase 2Cancer TreatmentEverolimus Versus SunitinibOncologyRadiation OncologyMolecular Oncology